Introduction of human papillomavirus DNA screening in the world

15 years of experience.

Philip E. Castle, Silvia de Sanjosé, You Lin Qiao, Jerome L. Belinson, Eduardo Lazcano-Ponce, Walter Kinney

Research output: Contribution to journalReview article

Abstract

The discovery of the necessary cause of cervical cancer, human papillomavirus (HPV), has led to important technological advances, including the development of molecular tests for HPV to identify women with cervical precancerous lesions. HPV testing has proven to be more sensitive and more reliable, albeit less specific, for detection of cervical precancer than cytologic methods of detection. As the result, HPV testing can reduce the incidence of cervical cancer within 4-5 years and reduce the mortality due to cervical cancer within 8 years compared to cytology. Additionally, a negative HPV test provides greater reassurance against cervical cancer than a negative Pap test. HPV testing, because of its attributes, is useful for screening out low-risk women who do not need further intervention for 5 or more years. Thus, HPV testing can shift the emphasis of the use of Pap testing or any other more specific diagnostic test from frequent use in the entire population to the ~10% subset of women who tested positive for the causal factor, HPV. Here, we highlight the current and future status of the introduction of HPV testing into routine cervical cancer screening. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.

Original languageEnglish (US)
JournalVaccine
Volume30 Suppl 5
StatePublished - Nov 20 2012
Externally publishedYes

Fingerprint

Papillomaviridae
screening
uterine cervical neoplasms
DNA
Uterine Cervical Neoplasms
testing
Papanicolaou Test
Papillomavirus Infections
Early Detection of Cancer
Routine Diagnostic Tests
lesions (animal)
cell biology
diagnostic techniques
Cell Biology
Vaccines
vaccines
incidence

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Castle, P. E., de Sanjosé, S., Qiao, Y. L., Belinson, J. L., Lazcano-Ponce, E., & Kinney, W. (2012). Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine, 30 Suppl 5.

Introduction of human papillomavirus DNA screening in the world : 15 years of experience. / Castle, Philip E.; de Sanjosé, Silvia; Qiao, You Lin; Belinson, Jerome L.; Lazcano-Ponce, Eduardo; Kinney, Walter.

In: Vaccine, Vol. 30 Suppl 5, 20.11.2012.

Research output: Contribution to journalReview article

Castle, PE, de Sanjosé, S, Qiao, YL, Belinson, JL, Lazcano-Ponce, E & Kinney, W 2012, 'Introduction of human papillomavirus DNA screening in the world: 15 years of experience.', Vaccine, vol. 30 Suppl 5.
Castle PE, de Sanjosé S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012 Nov 20;30 Suppl 5.
Castle, Philip E. ; de Sanjosé, Silvia ; Qiao, You Lin ; Belinson, Jerome L. ; Lazcano-Ponce, Eduardo ; Kinney, Walter. / Introduction of human papillomavirus DNA screening in the world : 15 years of experience. In: Vaccine. 2012 ; Vol. 30 Suppl 5.
@article{d844a7f9f22d498994ac4aaa46f6a705,
title = "Introduction of human papillomavirus DNA screening in the world: 15 years of experience.",
abstract = "The discovery of the necessary cause of cervical cancer, human papillomavirus (HPV), has led to important technological advances, including the development of molecular tests for HPV to identify women with cervical precancerous lesions. HPV testing has proven to be more sensitive and more reliable, albeit less specific, for detection of cervical precancer than cytologic methods of detection. As the result, HPV testing can reduce the incidence of cervical cancer within 4-5 years and reduce the mortality due to cervical cancer within 8 years compared to cytology. Additionally, a negative HPV test provides greater reassurance against cervical cancer than a negative Pap test. HPV testing, because of its attributes, is useful for screening out low-risk women who do not need further intervention for 5 or more years. Thus, HPV testing can shift the emphasis of the use of Pap testing or any other more specific diagnostic test from frequent use in the entire population to the ~10{\%} subset of women who tested positive for the causal factor, HPV. Here, we highlight the current and future status of the introduction of HPV testing into routine cervical cancer screening. This article forms part of a special supplement entitled {"}Comprehensive Control of HPV Infections and Related Diseases{"} Vaccine Volume 30, Supplement 5, 2012.",
author = "Castle, {Philip E.} and {de Sanjos{\'e}}, Silvia and Qiao, {You Lin} and Belinson, {Jerome L.} and Eduardo Lazcano-Ponce and Walter Kinney",
year = "2012",
month = "11",
day = "20",
language = "English (US)",
volume = "30 Suppl 5",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Introduction of human papillomavirus DNA screening in the world

T2 - 15 years of experience.

AU - Castle, Philip E.

AU - de Sanjosé, Silvia

AU - Qiao, You Lin

AU - Belinson, Jerome L.

AU - Lazcano-Ponce, Eduardo

AU - Kinney, Walter

PY - 2012/11/20

Y1 - 2012/11/20

N2 - The discovery of the necessary cause of cervical cancer, human papillomavirus (HPV), has led to important technological advances, including the development of molecular tests for HPV to identify women with cervical precancerous lesions. HPV testing has proven to be more sensitive and more reliable, albeit less specific, for detection of cervical precancer than cytologic methods of detection. As the result, HPV testing can reduce the incidence of cervical cancer within 4-5 years and reduce the mortality due to cervical cancer within 8 years compared to cytology. Additionally, a negative HPV test provides greater reassurance against cervical cancer than a negative Pap test. HPV testing, because of its attributes, is useful for screening out low-risk women who do not need further intervention for 5 or more years. Thus, HPV testing can shift the emphasis of the use of Pap testing or any other more specific diagnostic test from frequent use in the entire population to the ~10% subset of women who tested positive for the causal factor, HPV. Here, we highlight the current and future status of the introduction of HPV testing into routine cervical cancer screening. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.

AB - The discovery of the necessary cause of cervical cancer, human papillomavirus (HPV), has led to important technological advances, including the development of molecular tests for HPV to identify women with cervical precancerous lesions. HPV testing has proven to be more sensitive and more reliable, albeit less specific, for detection of cervical precancer than cytologic methods of detection. As the result, HPV testing can reduce the incidence of cervical cancer within 4-5 years and reduce the mortality due to cervical cancer within 8 years compared to cytology. Additionally, a negative HPV test provides greater reassurance against cervical cancer than a negative Pap test. HPV testing, because of its attributes, is useful for screening out low-risk women who do not need further intervention for 5 or more years. Thus, HPV testing can shift the emphasis of the use of Pap testing or any other more specific diagnostic test from frequent use in the entire population to the ~10% subset of women who tested positive for the causal factor, HPV. Here, we highlight the current and future status of the introduction of HPV testing into routine cervical cancer screening. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.

UR - http://www.scopus.com/inward/record.url?scp=84877107427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877107427&partnerID=8YFLogxK

M3 - Review article

VL - 30 Suppl 5

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -